Why Amylyx is pulling ALS drug Relyvrio from US market after study
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles
Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
Socialite Jasmine Hartin has been seen enjoying a beach snuggle with her new mystery man.Ms Hartin w2024-05-21New energy projects cater to Xizang's power needs
The Omatingga wind farm, the world's largest wind power project in an ultrahigh-altitude area, offic2024-05-21Beijing 2022 innovates green standard for snow venues
Workers prepare for an upcoming speed skating test event at the Capital Gymnasium in Beijing on Apri2024-05-21Highlights of 2022 Asian Open Figure Skating Trophy
Valerie Ang of Singapore competes during the Junior Women Short Program of the 2022 Asian Open Figur2024-05-21Georgia Republicans choose Amy Kremer, organizer of pro
COLUMBUS, Ga. (AP) — Georgia Republicans on Saturday elected to the Republican National Committee a2024-05-21Liaoning claims its third CBA title in team history
Yang Ming, head coach of Liaoning Flying Leopards hugs Zhao Jiwei, who has been awarded the Finals M2024-05-21
atest comment